4/14
07:30 am
glmd
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
High
Report
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
4/9
10:38 am
glmd
Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]
Low
Report
Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]
4/9
07:30 am
glmd
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
High
Report
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
3/31
04:30 pm
glmd
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]
Medium
Report
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]
3/31
04:15 pm
glmd
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Medium
Report
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
1/30
04:15 pm
glmd
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Medium
Report
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification